Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 31Stomach Neoplasms 4Neoplasms 4Cardiotoxicity 4Neoplasm Metastasis 3Brain Neoplasms 2Neurotoxicity Syndromes 1Neoplasms, Second Primary 1Neoplasm, Residual 1HER2-positive Breast Cancer 1HER2+ Breast Cancer 1Feasibility 1Fatigue 1Breast Cancer Organoids 1

Interventions

Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × HER2+ Breast Cancer × Trastuzumab × Clear all
NCT05931042 2023-07-05

Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review

Rawalpindi Medical College

Completed
1,209 enrolled
Breast

HER2+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡